Company Monopar Therapeutics Inc.

Equities

MNPR

US61023L1089

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.94 ^USD	+2.81%		+15.91%	+176.31%

May. 24	Monopar Therapeutics Names Karthik Radhakrishnan as CFO	MT
May. 24	Monopar Therapeutics Inc. Announces CFO Changes	CI

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

Number of employees: 10

Managers	Title	Age	Since
Chandler Robinson FOU	Founder	40	14-11-30
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Laura Kelly CTO	Chief Tech/Sci/R&D Officer	-	21-02-17
Andrew Cittadine COO	Chief Operating Officer	52	21-05-31
Patrice Rioux CTO	Chief Tech/Sci/R&D Officer	73	16-11-30

Members of the board	Title	Age	Since
Michael Brown BRD	Director/Board Member	67	14-11-30
Arthur Klausner BRD	Director/Board Member	64	17-07-31
Kim Tsuchimoto DFI	Director of Finance/CFO	61	15-05-31
Christopher Starr FOU	Founder	71	14-11-30
Raymond Anderson BRD	Director/Board Member	82	17-03-31
Chandler Robinson FOU	Founder	40	14-11-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	17,484,175	8,226,214 ( 47.05 %)	0	47.05 %

Name	Equities	%	Valuation
Tacticgem LLC 40.99 %	7,166,667	40.99 %	4 M $
Jeffrey Klunzinger 3.962 %	692,800	3.962 %	423 301 $
Chandler Robinson 1.431 %	250,131	1.431 %	152 830 $
Michael Brown 1.349 %	235,863	1.349 %	144 112 $
Millennium Management LLC 1.100 %	192,381	1.100 %	117 545 $
Andrew Cittadine 0.6727 %	117,624	0.6727 %	71 868 $
Christopher Starr 0.4305 %	75,263	0.4305 %	45 986 $
Kim Tsuchimoto 0.2887 %	50,470	0.2887 %	30 837 $
Vanguard Group, Inc. (Subfiler) 0.2583 %	45,167	0.2583 %	27 597 $
Geode Capital Management LLC 0.2356 %	41,199	0.2356 %	25 173 $

Monopar Therapeutics, Inc.

1000 Skokie Boulevard Suite 350

60091, Wilmette

+847 388 0349

http://www.monopartx.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.94 USD

Average target price

2.08 USD

Spread / Average Target

+121.28%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MONOPAR THERAPEUTICS INC.	+176.31%	16.44M
MODERNA, INC.	+40.80%	53.67B
IQVIA HOLDINGS INC.	-8.05%	38.76B
LONZA GROUP AG	+35.79%	38.86B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B

Other Biotechnology & Medical Research